Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27543742 | 0.95 | FFAR1 (0.42) | FFAR1PPARGSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30255216 | 0.84 | FFAR1 (0.38) | FFAR1PPARG | |
| SCHEMBL12371297 | 0.80 | FFAR1 (0.51) | FFAR1PPARGSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30255444 | 0.80 | CHRNB4 (0.50) | FFAR1KMT2A | |
| SCHEMBL30255130 | 0.78 | KMT2A (0.40) | FFAR1PPARGMAPTKMT2A | |
| SCHEMBL15265983 | 0.78 | SLC6A2 (0.37) | FFAR1SLC6A2SLC6A4SLC6A3GAA | |
| SCHEMBL6645372 | 0.77 | FFAR1 (0.52) | FFAR1PPARGSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8404390 | 0.77 | AR (0.51) | FFAR1PPARGMAPT | |
| SCHEMBL11343485 | 0.77 | FFAR1 (0.52) | FFAR1PPARGSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14509644 | 0.77 | FFAR1 (0.49) | FFAR1PPARGSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772313-B2 | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor | ABBOTT LABORATORIES (US) | 2014-07-08 | — | — | US | disclosed |
| US-8642642-B2 | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT LABORATORIES (US) | 2014-02-04 | — | — | US | disclosed |
| US-8470810-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8242102-B2 | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20120129883-A1 | BENZENESULFONYL OR SULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OFTHE SEROTONIN 5-HT6 RECEPTOR | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012059431-A1 | BENZENESULFONYL OR SULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2012-05-10 | — | — | WO | disclosed |
| EP-2139880-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-06-30 | — | — | US | disclosed |
| EP-2311802-A1 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311803-A1 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-7851463-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-12-14 | — | — | US | disclosed |
| EP-2139880-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008116831-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DIDORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2008-10-02 | — | — | WO | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129883-A1 | BENZENESULFONYL OR SULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OFTHE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR2A, HTR2B | FFAR1 338/4885PPARG 1374/4885SLC6A2 83/4885 |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, CHRNA3, CHRM3 | FFAR1 90/4885PPARG 520/4885SLC6A2 238/4885 |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR5A | FFAR1 162/4885PPARG 1122/4885SLC6A2 27/4885 |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | FFAR1 80/4885PPARG 458/4885SLC6A2 268/4885 |
| US-20110009380-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR2C, HTR3B, HTR1B | FFAR1 182/4885PPARG 1663/4885SLC6A2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.